ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.7987
0.03%
Brent Oil
84.17
0.26%
Bitcoin
62,859.31
-0.30%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Jounce Therapeutics Inc (JNCE)

  7. Jounce Therapeutics Inc (JNCE) Noticias

JNCE

Jounce Therapeutics (JNCE)

Jounce Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:JNCE
FechaHoraFuenteTítuloSímboloCompañía
14/02/202407:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JNCEJounce Therapeutics Inc
15/05/202306:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202315:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202315:35Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:JNCEJounce Therapeutics Inc
05/05/202305:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202307:40Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:31Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:JNCEJounce Therapeutics Inc
04/05/202306:08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:JNCEJounce Therapeutics Inc
03/05/202319:35GlobeNewswire Inc.Jounce Therapeutics Announces Closing of Tender OfferNASDAQ:JNCEJounce Therapeutics Inc
28/04/202313:48Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202306:55Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:JNCEJounce Therapeutics Inc
03/04/202301:00GlobeNewswire Inc.Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNASDAQ:JNCEJounce Therapeutics Inc
27/03/202313:12Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:JNCEJounce Therapeutics Inc
27/03/202308:00GlobeNewswire Inc.Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNASDAQ:JNCEJounce Therapeutics Inc
16/03/202315:30GlobeNewswire Inc.Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerNASDAQ:JNCEJounce Therapeutics Inc
14/03/202320:00GlobeNewswire Inc.Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesNASDAQ:JNCEJounce Therapeutics Inc
14/03/202316:01Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:JNCEJounce Therapeutics Inc
10/03/202308:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:JNCEJounce Therapeutics Inc
06/03/202315:00Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202315:56Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:JNCEJounce Therapeutics Inc
23/02/202301:30GlobeNewswire Inc.Redx and Jounce Announce Recommended Business CombinationNASDAQ:JNCEJounce Therapeutics Inc
22/02/202316:00GlobeNewswire Inc.Jounce Therapeutics Announces RestructuringNASDAQ:JNCEJounce Therapeutics Inc
14/02/202315:55Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:JNCEJounce Therapeutics Inc
09/01/202305:02Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:JNCEJounce Therapeutics Inc
27/12/202216:24Dow Jones NewsGilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202215:30Business WireGilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
27/12/202215:30GlobeNewswire Inc.Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics Inc
08/12/202206:50GlobeNewswire Inc.Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNASDAQ:JNCEJounce Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JNCE

Su Consulta Reciente

CCOM
US30
US 30
NYSE
DIS
Walt Disney
NYSE
JPM
JP Morgan Chase
USI
USTECH100
US Tech 100
AMEX
XLE
Energy Select Sector SPDR
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
CCOM
SILVER
SILVER
AMEX
SPY
SPDR S&P 500
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
NYSE
MCD
McDonalds
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados